RT Journal Article
SR Electronic
T1 Disruption of RFX family transcription factors causes autism, attention deficit/hyperactivity disorder, intellectual disability, and dysregulated behavior
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.09.20187104
DO 10.1101/2020.09.09.20187104
A1 Harris, Holly K.
A1 Nakayama, Tojo
A1 Lai, Jenny
A1 Zhao, Boxun
A1 Argyrou, Nikoleta
A1 Gubbels, Cynthia S.
A1 Soucy, Aubrie
A1 Genetti, Casie A.
A1 Rodan, Lance H.
A1 Tiller, George E.
A1 Lesca, Gaetan
A1 Gripp, Karen W.
A1 Asadollahi, Reza
A1 Hamosh, Ada
A1 Applegate, Carolyn D.
A1 Turnpenny, Peter D.
A1 Simon, Marleen E.H.
A1 Volker-Touw, Catharina (Nienke) M.L.
A1 van Gassen, Koen L.I.
A1 van Binsbergen, Ellen
A1 Pfundt, Rolph
A1 Gardeitchik, Thatjana
A1 de Vries, Bert B.A.
A1 Imken, Ladonna L.
A1 Buchanan, Catherine
A1 Willing, Marcia
A1 Toler, Tomi L.
A1 Fassi, Emily
A1 Baker, Laura
A1 Vansenne, Fleur
A1 Wang, Xiadong
A1 Ambrus, Julian L.
A1 Fannemel, Madeleine
A1 Posey, Jennifer E.
A1 Agolini, Emanuele
A1 Novelli, Antonio
A1 Rauch, Anita
A1 Boonsawat, Paranchai
A1 Fagerberg, Christina R.
A1 Larsen, Martin J.
A1 Kibaek, Maria
A1 Labalme, Audrey
A1 Poisson, Alice
A1 Payne, Katelyn K.
A1 Walsh, Laurence E.
A1 Aldinger, Kimberly
A1 Balciuniene, Jorune
A1 Skraban, Cara
A1 Gray, Christopher
A1 Murrell, Jill
A1 Bupp, Caleb P.
A1 Pascolini, Giulia
A1 Grammatico, Paola
A1 Broly, Martin
A1 Küry, Sébastien
A1 Nizon, Mathilde
A1 Rasool, Iqra Ghulam
A1 Zahoor, Muhammad Yasir
A1 Kraus, Cornelia
A1 Reis, André
A1 Iqbal, Muhammad
A1 Uguen, Kevin
A1 Audebert-Bellanger, Severine
A1 Ferec, Claude
A1 Redon, Sylvia
A1 Baker, Janice
A1 Wu, Yunhong
A1 Zampino, Guiseppe
A1 Syrbe, Steffan
A1 Brosse, Ines
A1 Jamra, Rami Abou
A1 Dobyns, William B.
A1 Cohen, Lilian L.
A1 Agrawal, Pankaj B.
A1 Beggs, Alan
A1 Yu, Timothy W.
YR 2020
UL http://medrxiv.org/content/early/2020/09/13/2020.09.09.20187104.abstract
AB Purpose We describe a novel neurobehavioral syndrome of autism spectrum disorder, intellectual disability, and attention deficit/hyperactivity disorder associated with de novo or inherited deleterious variants in members of the RFX family of genes. RFX genes are evolutionarily conserved transcription factors that act as master regulators of central nervous system development and ciliogenesis.Methods We assembled a cohort of 36 individuals (from 31 unrelated families) with de novo mutations in RFX3, RFX4, and RFX7. We describe their common clinical phenotypes and present bioinformatic analyses of expression patterns and downstream targets of these genes as they relate to other neurodevelopmental risk genes.Results These individuals share neurobehavioral features including autism spectrum disorder (ASD), intellectual disability, and attention-deficit/hyperactivity disorder (ADHD); other frequent features include hypersensitivity to sensory stimuli and sleep problems. RFX3, RFX4, and RFX7 are strongly expressed in developing and adult human brain, and X-box binding motifs as well as RFX ChIP-seq peaks are enriched in the cis-regulatory regions of known ASD risk genes.Conclusion These results establish deleterious variation in RFX3, RFX4, and RFX7 as important causes of monogenic intellectual disability, ADHD and ASD, and position these genes as potentially critical transcriptional regulators of neurobiological pathways associated with neurodevelopmental disease pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJL was supported by award T32GM007753 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. BZ was supported by the Manton Center Pilot Project Award and Rare Disease Research Fellowship. JEP and JRL were supported in part by the National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542). KU, SAB, CF, and SR were supported by the French Ministry of Health and the Health Regional Agency from Bretagne, Pays de la Loire and Centre Val de Loire (HUGODIMS 2, 2017). The DDD study is supported by the Wellcome Trust and the UK Department of Health Innovation Challenge Fund [HICF-1009-003] and the Wellcome Trust Sanger Institute [grant no. WT098051] (Nature 2015;519:223-8). TWY was supported by grant nos. NIH/NIMH R01MH113761, NICHD/NHGRI/NIH U19HD077671 and NIH/NICHD U24HD0938487, and by a SFARI Pilot Research Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Boston Children's Hospital IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in this manuscript is either provided in the main text/ supplementary material, or appropriately referenced (where derived from pre-existing, publicly accessible datasets).